Literature DB >> 20471889

Glucocorticoid-induced myopathy.

Rosa Maria Rodrigues Pereira1, Jozélio Freire de Carvalho.   

Abstract

Glucocorticoid-induced myopathy, characterized by muscle weakness without pain, fatigue and atrophy, is an adverse effect of glucocorticoid use and is the most common type of drug-induced myopathy. This muscle disturbance has a frequency of 60%, and it has been most often associated with fluorinated glucocorticoid preparations. Glucocorticoids have a direct catabolic effect on muscle, decreasing protein synthesis and increasing the rate of protein catabolism leading to muscle atrophy. In clinical practice, it is important to differentiate myopathy due to glucocorticoid from muscle inflammatory diseases. The treatment is based on reduction or, if possible, on discontinuation of the steroid. Fluorinated glucocorticoids such as dexamethasone should be replaced with nonfluorinated glucocorticoids such as prednisone. Other experimental treatments may be tried such as IGF-I, branched-chain amino acids, creatine, androgens such as testosterone, nandrolone and dehydroepiandrosterone (DHEA), and glutamine. Copyright Â
© 2010 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20471889     DOI: 10.1016/j.jbspin.2010.02.025

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  68 in total

1.  Resveratrol prevents dexamethasone-induced expression of the muscle atrophy-related ubiquitin ligases atrogin-1 and MuRF1 in cultured myotubes through a SIRT1-dependent mechanism.

Authors:  Nima Alamdari; Zaira Aversa; Estibaliz Castillero; Aniket Gurav; Victoria Petkova; Steven Tizio; Per-Olof Hasselgren
Journal:  Biochem Biophys Res Commun       Date:  2011-12-07       Impact factor: 3.575

2.  Strength of skeletal muscle and self-reported physical performance in Austrian glioblastoma-patients.

Authors:  Mohammad Keilani; Christoph Krall; Christine Marosi; Birgit Flechl; Karin Dieckmann; Georg Widhalm; Maximilian Marhold; Richard Crevenna
Journal:  Wien Klin Wochenschr       Date:  2012-06-12       Impact factor: 1.704

3.  Factors influencing spinal sagittal balance, bone mineral density, and Oswestry Disability Index outcome measures in patients with rheumatoid arthritis.

Authors:  Kazutaka Masamoto; Bungo Otsuki; Shunsuke Fujibayashi; Koichiro Shima; Hiromu Ito; Moritoshi Furu; Motomu Hashimoto; Masao Tanaka; Stephen Lyman; Hiroyuki Yoshitomi; Shimei Tanida; Tsuneyo Mimori; Shuichi Matsuda
Journal:  Eur Spine J       Date:  2017-11-28       Impact factor: 3.134

4.  Glucocorticoid-induced myopathy in the intensive care unit.

Authors:  Heidi Shil Eddelien; Henrik Westy Hoffmeyer; Eva Løbner Lund; Anne Øberg Lauritsen
Journal:  BMJ Case Rep       Date:  2015-05-24

5.  Corticosteroid use in neuro-oncology: an update.

Authors:  Patrick Roth; Caroline Happold; Michael Weller
Journal:  Neurooncol Pract       Date:  2014-10-09

Review 6.  Steroid myopathy: some unresolved issues.

Authors:  M A Minetto; F Lanfranco; G Motta; S Allasia; E Arvat; G D'Antona
Journal:  J Endocrinol Invest       Date:  2011-05       Impact factor: 4.256

Review 7.  Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity.

Authors:  Eleni I Kampylafka; Harry Alexopoulos; Marinos C Dalakas; Athanasios G Tzioufas
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 8.  Diagnostic work-up in steroid myopathy.

Authors:  Marco Alessandro Minetto; Valentina D'Angelo; Emanuela Arvat; Santosh Kesari
Journal:  Endocrine       Date:  2017-11-15       Impact factor: 3.633

9.  Quantitative ultrasound of muscle can detect corticosteroid effects.

Authors:  Maria G Martucci; Courtney E McIlduff; Carmen Shin; Hilda V Gutierrez; Joo Yeon Nam; Patricia Greenstein; Kester Phillips; Erik J Uhlmann; Eric T Wong; Seward B Rutkove
Journal:  Clin Neurophysiol       Date:  2019-05-10       Impact factor: 3.708

10.  Hypogonadism in DM1 and its relationship to erectile dysfunction.

Authors:  Giovanni Antonini; Alessandro Clemenzi; Elisabetta Bucci; Emanuela De Marco; Stefania Morino; Antonella Di Pasquale; Pamela Latino; Gilda Ruga; Andrea Lenzi; Nicola Vanacore; Antonio F Radicioni
Journal:  J Neurol       Date:  2011-02-23       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.